Genital TB and Infertility: The Honest Picture

Female genital tuberculosis is tuberculosis that has reached the fallopian tubes, the lining of the uterus, or the ovaries — almost always spreading through the bloodstream from an infection somewhere else, usually the lung, often years earlier and often never noticed. In most of the world it is a curiosity. In India it is one of the more important causes of infertility, and it is also one of the most carelessly diagnosed.

This page tries to hold both of those facts at once, because a woman being investigated for infertility in Gurugram can be harmed in either direction: by the diagnosis being missed, or by being given six months of chemotherapy she did not need.

How common it actually is

Across Indian studies, genital tuberculosis is reported in 1 to 19% of women investigated for infertility, with tertiary referral centres reporting up to 26% and some assisted-reproduction populations higher still. The comparable figure in infertility clinics in the United States and in Scandinavia is about 1%.

That contrast is the whole reason this page exists. An Indian woman with blocked tubes has a meaningfully different differential diagnosis from a woman in London with the same HSG report, and accepting "blocked tubes" as a complete explanation without asking why they are blocked is how it gets missed.

Be careful with the higher numbers, though. Figures like "genital TB causes 15 to 20% of infertility in India" circulate widely and come from narrative reviews without a pooled denominator. The range from actual studies is 1 to 19%, and where you sit in it depends heavily on which clinic is counting.

What it damages, and in what order

• Fallopian tubes — 90 to 100%, usually both. This is where the infection settles first and where most of the damage to fertility is done. The tube becomes scarred, rigid and blocked, and the delicate lining that moves the egg is destroyed.
• Endometrium — 50 to 80%, reached by spread downward from the tubes. This is the involvement that matters most for treatment decisions, because a destroyed lining cannot be repaired.
• Ovaries — 20 to 30%.
• Cervix — 5 to 15%, and the vagina or vulva in 1 to 2%.

Those percentages come from older surgical and autopsy series and every review quotes them slightly differently. Treat them as a shape rather than as precise measurements. The shape is what matters: this is a tubal disease that sometimes reaches the lining.

What a woman actually notices

Usually nothing, which is the difficulty. Infertility is the presenting problem in 60 to 80% of reproductive-age women with genital tuberculosis, and constitutional symptoms — fever, night sweats, weight loss — are much less common than people expect.

In a series of 374 infertile Indian women undergoing diagnostic laparoscopy, the commonest menstrual complaints were infrequent periods in 29.7% and scanty periods in 27.8%. Around a third reported poor appetite and about a third some weight loss. Primary infertility — never having conceived — accounted for 81.8%; the mean age was 27.5.

Two symptoms deserve particular attention because they point at the lining: periods that have become very scanty, or have stopped altogether, in a woman who is not conceiving. That combination is worth raising specifically.

The tests, and what each one actually proves

This is the section that decides whether a woman gets six months of treatment she needs or six months she does not. The tests are not interchangeable, and the ones that are easiest to order are the ones that prove least.

The denominator problem, which settles the argument

A systematic review pooling 77 studies and nearly 39,000 participants found the prevalence of tuberculosis infection in India to be about 36% overall — and in the 15 to 45 year age band, the infertility population, 52% (39–69). In Delhi it was 68%.

Read that again with a Mantoux result in your hand. Roughly half of Indian women of reproductive age will test positive whether or not there is a single organism anywhere near their fallopian tubes. A test that half the healthy population passes cannot be used to make a diagnosis in the other half. This is not a subtle statistical point; it is the reason exposure tests have no place in this decision.

The antibody test that should not exist

If you have been handed a report for "TB IgG" or "TB IgM", this matters.

• On 20 July 2011, after reviewing 94 studies, the World Health Organization issued a negative policy recommendation: commercial serological tests should not be used for diagnosing pulmonary or extrapulmonary tuberculosis. More than a million such tests were being sold each year at the time.
• On 7 June 2012, India prohibited the manufacture, sale, distribution and import of tuberculosis serodiagnostic test kits by gazette notification, under section 26A of the Drugs and Cosmetics Act 1940. The stated reason was that the kits were giving inconsistent and improper results leading to wrong diagnosis, and posed a risk to human beings.
• India was the first country in the world to impose that ban.

So a TB antibody result used in 2026 to justify treatment rests on a product that is not supposed to be on sale. If you have such a report, it is not evidence, and it is entirely reasonable to say so to whoever ordered it.

The over-treatment problem, with the numbers

Here is the finding that ought to be better known.

In that same series of 374 infertile women, endometrial TB-PCR was positive in 83.95%. In the same women, GeneXpert was positive in 18.56%, granulomas were seen in 15.50%, culture grew the organism in 6.41%, and the smear was positive in 4.81%.

Eighty-four per cent against nineteen per cent, in the same uterus, on the same day. Either five in six positive PCR results are detecting something that is not active disease, or every other test is missing four-fifths of it. The first explanation is considerably more likely.

Two further gaps are worth naming plainly. India's national guidelines on tuberculosis outside the lung contain no dedicated chapter on female genital tuberculosis — it falls implicitly under a generic urogenital heading with no specific graded recommendation. And the Indian federation of obstetric societies has published good-practice recommendations on a long list of subjects, none of them this one. In the absence of guidance, practice fills the vacuum.

One honest limitation: nobody has counted how many Indian women receive empirical treatment nationally. There is no registry and no survey. The 38% figure above is from a single centre, and anyone quoting you a national number is guessing.

So what is reasonable?

Not "never treat". Genital tuberculosis is real, it is progressive, and missing it has consequences. The defensible position is that the strength of the evidence should match the length of the treatment.

• A positive culture, a caseating granuloma, or a positive GeneXpert on an endometrial sample is solid ground. Treat.
• A suggestive HSG — beaded or rigid lead-pipe tubes, a golf-club appearance at a blocked end, a small or shrunken cavity, pelvic calcification — is a reason to investigate properly, not a diagnosis. Our page on reading an HSG report covers those appearances.
• A positive PCR alone, in a woman with normal tubes and a normal cavity, is the situation in which a pause and a second opinion are most worthwhile.
• A positive Mantoux, interferon test or antibody report is not a reason to start anything.
• Laparoscopy and hysteroscopy with directed sampling give the best combination of seeing the damage and getting material to test. Both are done at hospital.

Treatment, and what it does not do

The standard course is the same as for tuberculosis elsewhere: a two-month intensive phase of four drugs followed by a four-month continuation phase — six months in total. A randomised trial found no advantage to extending it to nine. Drug-resistant disease needs 18 to 24 months.

Now the part that is often not said clearly. Treatment sterilises the infection. It does not reverse the scarring. A tube that has been fibrosed shut does not reopen because the organism has been killed, and a lining that has been destroyed does not regrow.

• Pooled across 33 studies and 3,025 patients, spontaneous conception after treatment was 23.8% (15.0–32.6). Of those pregnancies, 64.4% ended in a live birth, 23.8% in miscarriage, and 9.2% were ectopic — a very high proportion, and a direct consequence of damaged tubes.
• Some series report considerably lower — one found 19.2% conception and only 7.2% live birth.
• Intrauterine insemination gave about 18.9%.

The ectopic figure deserves emphasis. A woman who conceives naturally after treatment for genital tuberculosis needs an early scan, not reassurance — see our page on ectopic pregnancy for why.

IVF, and when damage decides the outcome

• Pooled IVF pregnancy rate after genital tuberculosis: 37.9% (28.6–47.3), with a live birth in 67.4% of those pregnancies. Per patient, IVF achieved pregnancy at 5.75 times the rate of treatment alone.
• Where imaging is normal, a history of genital tuberculosis costs almost nothing — spontaneous conception 48.4% against IVF 49.2%. It is the damage that determines the prognosis, not the infection.
• Endometrial involvement is the one that changes things. Comparing women with endometrial tuberculosis against women with non-specific chronic endometritis, clinical pregnancy rates were similar — but miscarriage was 22.2% against 6.6%, an odds ratio of 10.60 (2.03–76.94). Getting pregnant is not the problem; staying pregnant is.
• A hydrosalpinx should be dealt with before IVF, as it should in any cause of tubal disease. Bilateral hydrosalpinges were associated with a 12% pregnancy rate against 24% for unilateral.
• IVF should not be done before the infection is treated — there is a risk of reactivation and of transmission to the baby.
• Where the lining has been destroyed but the ovaries are intact, gestational surrogacy is the route that is discussed in the literature, and in India it is governed by its own legislation.

Scarring inside the uterus

Genital tuberculosis is described in Indian series as an important and common cause of intrauterine adhesions — Asherman's syndrome — presenting exactly as you would expect: scanty or absent periods together with infertility. In one hysteroscopic series, 46% of the adhesions found were severe, grade III or IV.

This matters because the treatment of adhesions is surgical and the treatment of tuberculosis is medical, and a woman can need both. Our page on Asherman's syndrome covers what can and cannot be achieved with hysteroscopic surgery.

What happens at the clinic

Consultation, the full fertility assessment, going through your reports with you, blood tests, and prescribing and monitoring where treatment is genuinely indicated all happen at the clinic. HSG and all scans are arranged by referral — we do not run imaging here. Laparoscopy, hysteroscopy and endometrial sampling under anaesthetic are hospital procedures, and treatment for tuberculosis itself is given under the national programme or by a physician, with the fertility side coordinated alongside it.

If you have been told you have genital tuberculosis on the strength of a blood test or a single PCR result, and nobody has looked at your tubes or your cavity, that is a reasonable thing to want a second opinion about before starting six months of four-drug treatment. Bring every report, including the actual laboratory printouts rather than a summary.